Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review

INTRODUCTION: Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States. Few studies have investigated prescribing patterns among rheumatologists who have initiated secukinumab for the treatment of patients with...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Rheumatol Ther
Egile Nagusiak: Sunkureddi, Prashanth, Latremouille-Viau, Dominick, Meiselbach, Mark K., Xie, Jipan, Hur, Peter, Joshi, Reeti
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Healthcare 2019
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6393268/
https://ncbi.nlm.nih.gov/pubmed/30612321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-018-0137-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak